Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q3 2025 value amounting to $105000.0.

  • Whitehawk Therapeutics' Other Accumulated Expenses changed N/A to $105000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $105000.0, marking a year-over-year change of. This contributed to the annual value of $650000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Other Accumulated Expenses stood at $105000.0.
  • Whitehawk Therapeutics' Other Accumulated Expenses' 5-year high stood at $1.5 million during Q3 2021, with a 5-year trough of $10805.0 in Q2 2021.
  • In the last 4 years, Whitehawk Therapeutics' Other Accumulated Expenses had a median value of $305000.0 in 2021 and averaged $450804.8.
  • The largest annual percentage gain for Whitehawk Therapeutics' Other Accumulated Expenses in the last 5 years was 697632.42% (2021), contrasted with its biggest fall of 6387.86% (2021).
  • Whitehawk Therapeutics' Other Accumulated Expenses (Quarter) stood at $496000.0 in 2021, then skyrocketed by 34.68% to $668000.0 in 2022, then fell by 2.69% to $650000.0 in 2024, then plummeted by 83.85% to $105000.0 in 2025.
  • Its Other Accumulated Expenses stands at $105000.0 for Q3 2025, versus $114000.0 for Q2 2025 and $650000.0 for Q4 2024.